Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Butt

Showing results (261-270 of 309) with videos related to

Pageof 31
Sort By:
Journal of the American Heart Association|April 23, 2025
Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HFMisato Chimura, Jawad H Butt, Shingo Matsumoto, et al.
European Journal of Heart Failure|November 20, 2024
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HFSharmistha Datta Gupta, Jawad H Butt, Eoghan G M McMurray, et al.
European Journal of Heart Failure|April 13, 2025
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
CJC Open|May 24, 2021
Association Between Perioperative Atrial Fibrillation and Long-term Risks of Stroke and Death in Noncardiac Surgery: Systematic Review and Meta-analysisJessica T Huynh, Jeff S Healey, Kevin J Um, et al.
Neuro-Oncology Practice|May 23, 2022
A randomized feasibility study evaluating temozolomide circadian medicine in patients with gliomaAnna R Damato, Ruth G N Katumba, Jingqin Luo, et al.
European Journal of Heart Failure|August 19, 2024
Anthropometric measures and long-term mortality in non-ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradoxJawad H Butt, Jens Jakob Thune, Jens C Nielsen, et al.
European Journal of Heart Failure|February 17, 2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trialJawad H Butt, Jose C Nicolau, Subodh Verma, et al.
Neuroepidemiology|April 26, 2021
The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016-2018: The Ohio Population-Based ALS RegistryAngeline S Andrew, Erik P Pioro, Meifang Li, et al.
JACC. Heart Failure|July 28, 2022
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HFJawad H Butt, Pooja Dewan, Ersilia M DeFilippis, et al.
Pageof 31

Showing results (261-270 of 309) with videos related to

Sort By:
Pageof 31
Journal of the American Heart Association|April 23, 2025
Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HFMisato Chimura, Jawad H Butt, Shingo Matsumoto, et al.
European Journal of Heart Failure|November 20, 2024
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HFSharmistha Datta Gupta, Jawad H Butt, Eoghan G M McMurray, et al.
European Journal of Heart Failure|April 13, 2025
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
CJC Open|May 24, 2021
Association Between Perioperative Atrial Fibrillation and Long-term Risks of Stroke and Death in Noncardiac Surgery: Systematic Review and Meta-analysisJessica T Huynh, Jeff S Healey, Kevin J Um, et al.
Neuro-Oncology Practice|May 23, 2022
A randomized feasibility study evaluating temozolomide circadian medicine in patients with gliomaAnna R Damato, Ruth G N Katumba, Jingqin Luo, et al.
European Journal of Heart Failure|August 19, 2024
Anthropometric measures and long-term mortality in non-ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradoxJawad H Butt, Jens Jakob Thune, Jens C Nielsen, et al.
European Journal of Heart Failure|February 17, 2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trialJawad H Butt, Jose C Nicolau, Subodh Verma, et al.
Neuroepidemiology|April 26, 2021
The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016-2018: The Ohio Population-Based ALS RegistryAngeline S Andrew, Erik P Pioro, Meifang Li, et al.
JACC. Heart Failure|July 28, 2022
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HFJawad H Butt, Pooja Dewan, Ersilia M DeFilippis, et al.
Pageof 31